Legalization of Marijuana Linked with Decrease in Synthetic Cannabinoid Poisonings

Aug.09.2022
Legalizing marijuana decreases reports of synthetic marijuana poisoning by 37%, according to a study by Washington State University. Synthetic marijuana, also known as K2, Spice, or AK-47, is highly toxic and difficult to detect in drug tests.

Synthetic cannabinoids, also known by street names such as K2, Spice, or AK-47, are dangerous designer drugs that appear to have less appeal in states where natural forms of marijuana have already been legalized.


A study led by Washington State University has found that states where marijuana is legalized have seen a 37% decrease in reports of synthetic cannabinoid intoxication compared to states that restrict marijuana. These findings show that it is difficult to detect synthetic cannabinoid use with standard drug tests.


Tracy Klein, associate professor of nursing at WSU, stated, "This study demonstrates some potential public health benefits of legalizing and regulating marijuana use among adults. Based on prior research and the findings of this study, it appears that individuals may opt for products with lower toxicity levels.


Synthetic cannabinoids are not actually marijuana. They are named as such because they share similarities with the psychoactive components of the marijuana plant, tetrahydrocannabinol (THC) and cannabidiol (CBD), on the cannabinoid receptors of the brain. However, illegal synthetics have binding powers up to 100 times higher than these receptors, and lack any intermediary components found in full-plant marijuana such as THC or CBD. As a result, synthetic cannabinoids carry a high toxicity and can lead to serious harm, even death.


In a study published in the Journal of Clinical Toxicology, researchers analyzed data from the National Poison Data System from 2016 to 2019, prior to the outbreak of the pandemic. They focused only on states with relatively stable policies during those years and classified them into three categories: those with lenient policies, like Washington state, which allow for both medical and recreational use of marijuana for adults; those with medical-only policies, like Hawaii, where marijuana is only allowed for medical purposes; and those with restrictive policies, like Idaho, where almost all marijuana use is prohibited.


In this sample, 7600 individuals received reports of poisonings related to the use of synthetic cannabinoids, with approximately 65% requiring medical care. There were also 61 deaths. Researchers found that during this period, reports of poisonings related to synthetics decreased overall, but medical referrals decreased by 13% and dropped by 37% in states where they were legal.


Early research from JAMA Open has found that from 2017 to 2019, poison control calls related to natural marijuana use have increased across the United States. The increase, however, is primarily driven by plant-based e-cigarette materials and edibles that may contain high levels of THC. In contrast, during the same period, there has been a decrease in poison control calls related to whole-plant marijuana.


Although some synthetic cannabinoids have been used for medical purposes, namely dronabinol and nabiximols primarily used to treat nausea related to cancer treatment, illegal versions are illegal in all states and have no medical purpose. Enforcement may be difficult as manufacturers frequently change their formulas. They are also often not detected in standard urine drug tests, which may be one reason people in restricted states use them.


Klein stated that further research is needed to better understand the usage of these drugs and the differences between them. She noted that the dataset of this research does not include Delta-8, a synthetically derived chemical that is becoming more popular, which is sold as a less potent form of Delta-9, a psychoactive cannabinoid found in natural plant products.


Klein, the Assistant Director of WSU's marijuana policy, research, and outreach center, stated, "We are aware that there are many cannabis derivatives currently being developed on the market - regulatory agencies are working to catch up.


The author points out that current research may underestimate the use of these drugs as they are difficult to detect.


You cannot easily detect illegal marijuana compounds. Often, we only discover that patients have used them because they are hospitalized or have already died," Klein said.


The co-authors of this study, apart from Klein, include Julie Dilley from the Multnomah County Health Department and the Oregon Health Authority, Janessa Graves from the WSU College of Nursing, and Erica Liebelt from the University of Arkansas for Medical Sciences.


Statement:


This article is compiled from third-party information and is intended solely for industry professionals for educational purposes.


This article does not reflect the views of 2FIRSTS and 2FIRSTS cannot confirm the veracity or accuracy of the content. The translation of this article is intended solely for industry exchange and research purposes.


Due to limitations in translation ability, the translated article may not perfectly reflect the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong and Taiwan-related, and foreign expressions and stances.


The compiled information is the property of the original media and author. If there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Reynolds American launches U.S. investment plan: to invest $3.2 billion to expand capacity and advance a shift toward smokeless products
Reynolds American launches U.S. investment plan: to invest $3.2 billion to expand capacity and advance a shift toward smokeless products
Reynolds American says it will invest more than $3.2 billion across its U.S. operations by 2030. The investment began in 2024 and is expected to support more than 2,000 direct and indirect jobs. The company says the plan covers modernization and expansion of manufacturing facilities, scaling innovation and production, supply-chain initiatives and employee training, and also references its R&D spending and related site footprint.
Mar.06 by 2FIRSTS.ai
Australian police seize tobacco and vape products in roadside stop: goods valued at A$784,950
Australian police seize tobacco and vape products in roadside stop: goods valued at A$784,950
Australian police say that during a roadside inspection in southern New South Wales, they seized 293,200 cigarettes, 265kg of hard-pressed tobacco leaf and 2,290 vape products from a van bearing Victorian number plates, with an estimated street value of A$784,950.
Feb.26 by 2FIRSTS.ai
Pakistan Senate health panel weighs possible vape ban
Pakistan Senate health panel weighs possible vape ban
Sources say Pakistan’s Senate Standing Committee on Health is deliberating whether to impose a ban on vaping products, after holding a meeting on the health implications of vaping and the rising use of e-cigarettes nationwide.
Mar.04 by 2FIRSTS.ai
Sesh Launches 200-Pouch Refill Bag, Expanding Retail Unit Size in U.S. Nicotine Pouch Market
Sesh Launches 200-Pouch Refill Bag, Expanding Retail Unit Size in U.S. Nicotine Pouch Market
According to a LinkedIn post published by Sesh CMO Josh Metz on February 25, 2026, Sesh Products has introduced a 200-pouch nicotine pouch refill bag sold with a reusable metal can. In a U.S. MO market dominated by 20-pouch plastic cans, the product offers a larger retail unit size. The company lists a standard price of USD 49.99, with a uniform 15% discount currently applied, bringing the price to USD 42.49.
Innovation
Feb.25
Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
The EPO Technical Board of Appeal 3.2.02 (T 1319/24) revoked VMR Products LLC’s EP3613453 “VAPORIZER” patent after finding that a 2012 YouTube video of the Innokin iTaste VV (D3) disclosed the claimed electrical contact arrangement. Opponents Nicoventures Trading Ltd (BAT subsidiary) and Philip Morris Products S.A. prevailed.
BATPMI
Feb.17
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
FDA Authorizes Glas Vape but Flavor Hopes Fall Short
The FDA has added Glas products to its authorized electronic nicotine delivery systems (ENDS) list, granting Marketing Granted Orders (MGOs) to the Glas G DEVICE and a BLONDE TOBACCO pod. The decision expands the number of FDA-authorized ENDS products to 41, marking the first new authorization since Juul’s approvals in July 2025. However, widely anticipated non-tobacco flavored products were not approved.
Mar.13